Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

NCT04924699 is registered in ClinicalTrials.gov with Shanghai Miracogen Inc. as lead sponsor.

NCT NCT04924699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04924699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Shanghai Miracogen Inc.
Phase
Phase 2/3
Overall status
Unknown status
Start date
June 30, 2021
Completion date
October 31, 2023
Enrollment
350 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, metastatic breast cancer